Literature DB >> 24918945

Predictors of insulin resistance in pediatric burn injury survivors 24 to 36 months postburn.

Maria Chondronikola1, Walter J Meyer, Labros S Sidossis, Sylvia Ojeda, Joanna Huddleston, Pamela Stevens, Elisabet Børsheim, Oscar E Suman, Celeste C Finnerty, David N Herndon.   

Abstract

Burn injury is a dramatic event with acute and chronic consequences including insulin resistance. However, factors associated with insulin resistance have not been previously investigated. The purpose of this study was to identify factors associated with long-term insulin resistance in pediatric burn injury survivors. The study sample consisted of 61 pediatric burn injury survivors 24 to 36 months after the burn injury, who underwent an oral glucose tolerance test. To assess insulin resistance, the authors calculated the area under the curve for glucose and insulin. The diagnostic criteria of the American Diabetes Association were used to define individuals with impaired glucose metabolism. Additional data collected include body composition, anthropometric measurements, burn characteristics, and demographic information. The data were analyzed using multivariate linear regression analysis. Approximately 12% of the patients met the criteria for impaired glucose metabolism. After adjusting for possible confounders, burn size, age, and body fat percentage were associated with the area under the curve for glucose (P < .05 for all). Time postburn and lean mass were inversely associated with the area under the curve for glucose (P < .05 for both). Similarly, older age predicted higher insulin area under the curve. The results indicate that a significant proportion of pediatric injury survivors suffer from glucose abnormalities 24 to 36 months postburn. Burn size, time postburn, age, lean mass, and adiposity are significant predictors of insulin resistance in pediatric burn injury survivors. Clinical evaluation and screening for abnormal glucose metabolism should be emphasized in patients with large burns, older age, and survivors with high body fat.

Entities:  

Mesh:

Year:  2014        PMID: 24918945      PMCID: PMC4162820          DOI: 10.1097/BCR.0000000000000017

Source DB:  PubMed          Journal:  J Burn Care Res        ISSN: 1559-047X            Impact factor:   1.845


  47 in total

Review 1.  Diabetic retinopathy.

Authors:  Donald S Fong; Lloyd P Aiello; Frederick L Ferris; Ronald Klein
Journal:  Diabetes Care       Date:  2004-10       Impact factor: 19.112

2.  Insulin resistance as a predictor of age-related diseases.

Authors:  F S Facchini; N Hua; F Abbasi; G M Reaven
Journal:  J Clin Endocrinol Metab       Date:  2001-08       Impact factor: 5.958

Review 3.  Diabetes and atherosclerosis: epidemiology, pathophysiology, and management.

Authors:  Joshua A Beckman; Mark A Creager; Peter Libby
Journal:  JAMA       Date:  2002-05-15       Impact factor: 56.272

4.  Renal function changes in diabetes.

Authors:  C E Mogensen
Journal:  Diabetes       Date:  1976       Impact factor: 9.461

5.  Validation of insulin sensitivity indices from oral glucose tolerance test parameters in obese children and adolescents.

Authors:  Catherine W Yeckel; Ram Weiss; James Dziura; Sara E Taksali; Sylvie Dufour; Tania S Burgert; William V Tamborlane; Sonia Caprio
Journal:  J Clin Endocrinol Metab       Date:  2004-03       Impact factor: 5.958

Review 6.  Insulin resistance and hyperglycemia in critical illness: role of insulin in glycemic control.

Authors:  Lindsay E Robinson; Mary H van Soeren
Journal:  AACN Clin Issues       Date:  2004 Jan-Mar

7.  Association between the insulin resistance of puberty and the insulin-like growth factor-I/growth hormone axis.

Authors:  Antoinette Moran; David R Jacobs; Julia Steinberger; Pinchas Cohen; Ching-Ping Hong; Ronald Prineas; Alan R Sinaiko
Journal:  J Clin Endocrinol Metab       Date:  2002-10       Impact factor: 5.958

8.  Relative influence of glucose and insulin on peripheral amino acid metabolism in severely burned patients.

Authors:  Dennis C Gore; Steven E Wolf; David N Herndon; Robert R Wolfe
Journal:  JPEN J Parenter Enteral Nutr       Date:  2002 Sep-Oct       Impact factor: 4.016

9.  Perioperative hyperglycemia is a strong correlate of postoperative infection in type II diabetic patients after coronary artery bypass grafting.

Authors:  Murat Guvener; Ilhan Pasaoglu; Metin Demircin; Mehmet Oc
Journal:  Endocr J       Date:  2002-10       Impact factor: 2.349

10.  Establishing a standard definition for child overweight and obesity worldwide: international survey.

Authors:  T J Cole; M C Bellizzi; K M Flegal; W H Dietz
Journal:  BMJ       Date:  2000-05-06
View more
  5 in total

1.  Effects of the nephrilin peptide on post-burn glycemic control, renal function, fat and lean body mass, and wound healing.

Authors:  Desmond D Mascarenhas; Amina El Ayadi; Michael Wetzel; Anesh Prasai; Randy Mifflin; Jayson Jay; David N Herndon; Celeste C Finnerty
Journal:  Int J Burns Trauma       Date:  2016-11-30

2.  Fifty Years of Burn Care at Shriners Hospitals for Children, Galveston.

Authors:  Karel D Čapek; Derek M Culnan; Manubhai H Desai; David N Herndon
Journal:  Ann Plast Surg       Date:  2018-03       Impact factor: 1.539

3.  Covalent modification of nephrilin peptide with valproic acid increases its efficacy as a therapeutic in burn trauma.

Authors:  Desmond D Mascarenhas; Puja Ravikumar; Edward P Amento
Journal:  Burns Open       Date:  2020-06-11

4.  Positive effects of ferric iron on the systemic efficacy of nephrilin peptide in burn trauma.

Authors:  Desmond D Mascarenhas; Amina El Ayadi; Puja Ravikumar; Gyeong Jin Kang; Tammy Langer; Carlos Moreno; Edward P Amento
Journal:  Scars Burn Heal       Date:  2020-06-19

5.  Coenzyme Q10 protects against burn-induced mitochondrial dysfunction and impaired insulin signaling in mouse skeletal muscle.

Authors:  Harumasa Nakazawa; Kazuhiro Ikeda; Shohei Shinozaki; Shingo Yasuhara; Yong-Ming Yu; J A Jeevendra Martyn; Ronald G Tompkins; Tomoko Yorozu; Satoshi Inoue; Masao Kaneki
Journal:  FEBS Open Bio       Date:  2019-01-19       Impact factor: 2.693

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.